Eisai to Market Orion’s Two Parkinson’s Disease Drugs in China

Eisai has entered into an agreement to market and distribute two Parkinson’s disease drugs of Finland-based Orion Corporation, Comtan® (entacapone) and Stalevo® (levodopa/entacapone/carbidopa combination agent), in China. Under the terms of the agreement, Eisai acquired from Orion the exclusive rights to market the two products in China, and began distribution and promotion through its Chinese subsidiary Eisai China Inc. (Location: Suzhou, Jiangsu Province). Financial details were not disclosed. More details.... Stock symbols (TYO: 4523) (HEL: ORNBV) Share this with colleagues: // //